利伐沙班在健康人体受试者中的药代动力学特性。
Pharmacokinetic Properties of Rivaroxaban in Healthy Human Subjects.
作者信息
Bratsos Sosipatros
机构信息
Cardiology, Imperial College London, London, GBR.
出版信息
Cureus. 2019 Aug 25;11(8):e5484. doi: 10.7759/cureus.5484.
Abstract
Direct oral anticoagulants (DOACs) have predictable pharmacokinetics and pharmacodynamics, limited potential for drug to drug interactions, and can be given at fixed doses without the need for routine coagulation monitoring, which makes them a very attractive alternative to vitamin K antagonists. DOACs act by specifically targeting a single coagulation factor, such as Factor Xa or thrombin. Rivaroxaban is a direct Factor Xa inhibitor and has been approved for use in several thromboembolic disorders, such as the prevention of stroke and systemic embolism in adults with non-valvular atrial fibrillation and the prevention of recurrent deep vein thrombosis and pulmonary embolism in adult patients. This review aimed to provide an overview of the mechanism of action of rivaroxaban and outline its pharmacokinetic properties (absorption, distribution, metabolism, and excretion) in healthy adult subjects.
摘要
直接口服抗凝剂（DOACs）具有可预测的药代动力学和药效学，药物相互作用的可能性有限，并且可以固定剂量给药，无需常规凝血监测，这使其成为维生素K拮抗剂非常有吸引力的替代品。DOACs通过特异性靶向单一凝血因子（如因子Xa或凝血酶）发挥作用。利伐沙班是一种直接的因子Xa抑制剂，已被批准用于多种血栓栓塞性疾病，如预防非瓣膜性心房颤动成人的中风和全身性栓塞，以及预防成年患者复发性深静脉血栓形成和肺栓塞。本综述旨在概述利伐沙班的作用机制，并概述其在健康成年受试者中的药代动力学特性（吸收、分布、代谢和排泄）。
相似文献
1
Pharmacokinetic Properties of Rivaroxaban in Healthy Human Subjects.利伐沙班在健康人体受试者中的药代动力学特性。
Cureus. 2019 Aug 25;11(8):e5484. doi: 10.7759/cureus.5484.
2
Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions.非维生素K拮抗剂口服抗凝药在心血管疾病管理中的应用：证据与未解决的问题
J Clin Pharm Ther. 2014 Apr;39(2):118-35. doi: 10.1111/jcpt.12122. Epub 2014 Jan 3.
3
Pharmacokinetics and pharmacodynamics of rivaroxaban--an oral, direct factor Xa inhibitor.利伐沙班的药代动力学和药效学——一种口服直接Xa因子抑制剂
Curr Clin Pharmacol. 2014 Feb;9(1):75-83. doi: 10.2174/1574884708666131111204658.
4
Rivaroxaban for the treatment and prevention of thromboembolic disease.利伐沙班用于治疗和预防血栓栓塞性疾病。
J Pharm Pharmacol. 2015 Aug;67(8):1119-32. doi: 10.1111/jphp.12387. Epub 2015 Jun 9.
5
Rivaroxaban: practical considerations for ensuring safety and efficacy.利伐沙班：确保安全性和有效性的实际考量
Pharmacotherapy. 2013 Nov;33(11):1223-45. doi: 10.1002/phar.1289. Epub 2013 May 26.
6
Rivaroxaban: a novel, oral, direct factor Xa inhibitor.利伐沙班：一种新型口服直接凝血因子Xa抑制剂。
Pharmacotherapy. 2009 Feb;29(2):167-81. doi: 10.1592/phco.29.2.167.
7
Rivaroxaban in the Prevention of Stroke and Systemic Embolism in Patients with Non-Valvular Atrial Fibrillation: Clinical Implications of the ROCKET AF Trial and Its Subanalyses.利伐沙班预防非瓣膜性心房颤动患者的卒中和全身性栓塞：ROCKET AF试验及其亚组分析的临床意义
Am J Cardiovasc Drugs. 2015 Dec;15(6):395-401. doi: 10.1007/s40256-015-0127-2.
8
Italian intersociety consensus on DOAC use in internal medicine.意大利内科医学领域关于直接口服抗凝剂（DOAC）使用的跨学会共识。
Intern Emerg Med. 2017 Apr;12(3):387-406. doi: 10.1007/s11739-017-1628-6. Epub 2017 Feb 13.
9
[Rivaroxaban in high-risk patients].[利伐沙班用于高危患者]
Vnitr Lek. 2017 Summer;63(6):424-430.
10
New Direct Oral Anticoagulants (DOAC) and Their Use Today.新型直接口服抗凝剂（DOAC）及其当前应用
Dent J (Basel). 2016 Mar 11;4(1):5. doi: 10.3390/dj4010005.
引用本文的文献
1
Development and evaluation of the rivaroxaban loaded nanostructured lipid carriers for improved oral bioavailability and safety.用于提高口服生物利用度和安全性的利伐沙班纳米结构脂质载体的研制与评价
Sci Rep. 2025 Jul 2;15(1):23350. doi: 10.1038/s41598-025-06926-6.
2
American Society of Hematology/International Society on Thrombosis and Haemostasis 2024 updated guidelines for treatment of venous thromboembolism in pediatric patients.美国血液学会/国际血栓与止血学会2024年儿童静脉血栓栓塞症治疗更新指南。
Blood Adv. 2025 May 27;9(10):2587-2636. doi: 10.1182/bloodadvances.2024015328.
3
pharmacokinetic interactions of ribociclib with rivaroxaban and apixaban in rats: implications for increased drug exposure and dose adjustments.瑞博西尼与利伐沙班和阿哌沙班在大鼠体内的药代动力学相互作用：对药物暴露增加和剂量调整的影响
Front Pharmacol. 2025 Mar 31;16:1530806. doi: 10.3389/fphar.2025.1530806. eCollection 2025.
4
RSM and AI based machine learning for quality by design development of rivaroxaban push-pull osmotic tablets and its PBPK modeling.基于响应面法（RSM）和人工智能的机器学习用于利伐沙班推拉渗透泵片的质量源于设计开发及其生理药代动力学（PBPK）建模
Sci Rep. 2025 Mar 7;15(1):7922. doi: 10.1038/s41598-025-91601-z.
5
Beyond Anticoagulation: A Comprehensive Review of Non-Vitamin K Oral Anticoagulants (NOACs) in Inflammation and Protease-Activated Receptor Signaling.超越抗凝：非维生素 K 口服抗凝剂（NOACs）在炎症和蛋白酶激活受体信号转导中的综合评价。
Int J Mol Sci. 2024 Aug 10;25(16):8727. doi: 10.3390/ijms25168727.
6
Direct Oral FXa Inhibitors Binding to Human Serum Albumin: Spectroscopic, Calorimetric, and Computational Studies.直接口服 FXa 抑制剂与人血清白蛋白的结合：光谱、量热和计算研究。
Int J Mol Sci. 2023 Mar 3;24(5):4900. doi: 10.3390/ijms24054900.
7
Improper administration: Silent culprit of drug therapy problems.用药不当：药物治疗问题的隐性罪魁祸首。
Can Fam Physician. 2023 Feb;69(2):107-112. doi: 10.46747/cfp.6902107.
8
Rivaroxaban Pharmacokinetics in Obese Subjects: A Systematic Review.利伐沙班在肥胖受试者中的药代动力学：系统评价。
Clin Pharmacokinet. 2022 Dec;61(12):1677-1695. doi: 10.1007/s40262-022-01160-z. Epub 2022 Oct 6.
9
Evaluation of safety and efficacy outcomes of direct oral anticoagulants versus warfarin in normal and extreme body weights for the treatment of atrial fibrillation or venous thromboembolism.直接口服抗凝剂与华法林在正常体重和极端体重患者中治疗心房颤动或静脉血栓栓塞的安全性和有效性结果评估。
J Thromb Thrombolysis. 2022 Aug;54(2):276-286. doi: 10.1007/s11239-022-02668-8. Epub 2022 Jun 10.
10
Antithrombotic drug removal from whole blood using Haemoadsorption with a porous polymer bead sorbent.使用多孔聚合物珠吸附剂从全血中去除抗血栓药物。
Eur Heart J Cardiovasc Pharmacother. 2022 Dec 2;8(8):847-856. doi: 10.1093/ehjcvp/pvac036.
本文引用的文献
1
Factor Xa Inhibitory Profile of Apixaban, Betrixaban, Edoxaban, and Rivaroxaban Does Not Fully Reflect Their Biologic Spectrum.阿哌沙班、贝曲沙班、依度沙班和利伐沙班的 Xa 因子抑制谱并不能完全反映其生物学谱。
Clin Appl Thromb Hemost. 2019 Jan-Dec;25:1076029619847524. doi: 10.1177/1076029619847524.
2
Structural and Functional Changes With the Aging Kidney.肾脏衰老过程中的结构和功能变化。
Adv Chronic Kidney Dis. 2016 Jan;23(1):19-28. doi: 10.1053/j.ackd.2015.08.004.
3
Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC registry.日常护理中利伐沙班出血的发生率、管理及结局：德累斯顿新型口服抗凝药登记研究结果
Blood. 2014 Aug 7;124(6):955-62. doi: 10.1182/blood-2014-03-563577. Epub 2014 May 23.
4
Polymorphic cytochrome P450 enzymes (CYPs) and their role in personalized therapy.多态性细胞色素P450酶（CYPs）及其在个性化治疗中的作用。
PLoS One. 2013 Dec 10;8(12):e82562. doi: 10.1371/journal.pone.0082562. eCollection 2013.
5
The questionable use of unequal allocation in confirmatory trials.确证性试验中不均衡分配的质疑。
Neurology. 2014 Jan 7;82(1):77-9. doi: 10.1212/01.wnl.0000438226.10353.1c. Epub 2013 Dec 4.
6
Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban.利伐沙班的临床药代动力学和药效学特征。
Clin Pharmacokinet. 2014 Jan;53(1):1-16. doi: 10.1007/s40262-013-0100-7.
7
The effect of food on the absorption and pharmacokinetics of rivaroxaban.食物对利伐沙班吸收及药代动力学的影响。
Int J Clin Pharmacol Ther. 2013 Jul;51(7):549-61. doi: 10.5414/CP201812.
8
The influence of age and gender on the pharmacokinetics and pharmacodynamics of rivaroxaban--an oral, direct Factor Xa inhibitor.年龄和性别对利伐沙班（一种口服、直接的 Xa 因子抑制剂）药代动力学和药效学的影响。
J Clin Pharmacol. 2013 Mar;53(3):249-55. doi: 10.1002/jcph.5. Epub 2013 Feb 4.
9
Co-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects.利伐沙班与具有相同消除途径的药物联合用药：健康受试者的药代动力学影响。
Br J Clin Pharmacol. 2013 Sep;76(3):455-66. doi: 10.1111/bcp.12075.
10
Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.口服抗凝治疗：抗血栓治疗和血栓预防，第 9 版：美国胸科医师学会基于证据的临床实践指南。
Chest. 2012 Feb;141(2 Suppl):e44S-e88S. doi: 10.1378/chest.11-2292.
Zotero 插件